Chronic diseases are major cost factors in the healthcare systems of industrialized countries worldwide due to the need for lifelong treatment and care.

Of the direct health costs - over 430 billion in Germany - the costs of cardiovascular and kidney diseases (including heart failure) account for around 25%.

Of this,after 2 yearsalready aSavings of 30%, up to 30 billion annually. Furthermore, the dynamic spread of these diseases, one of the major cost drivers, can be stopped.

The timely detection of chronic diseases through proteomic tests at the molecular level, before organ damage has occurred, enables

• timely initiation of therapy,
• improved therapy compliance through first-time defined disease status,
• the individualized, targeted treatment of the patient through proteome-based monitoring,
• ultimately preventing the onset of a chronic disease.